Ординатура / Офтальмология / Английские материалы / Oxford American Handbook of Ophthalmology_Tsai, Denniston, Murray_2011
.pdf
316 CHAPTER 11 Uveitis
Classification of uveitis (1)
The classification of uveitis may be anatomical, clinical, pathological, or etiological, and all of these may be useful in defining a uveitis entity. Anatomical classification has been formalized by the International Uveitis Study Group (ISUG) and amended by the Standardization of Uveitis Nomenclature (SUN) group (2005) (Table 11.1).
Anterior uveitis accounts for the majority of uveitis cases in Western populations. A much smaller proportion is made up of posterior, intermediate, and panuveitis.
Anatomical classification
Table 11.1 Anatomical classification of uveitis (SUN 2005)
Type |
Primary site of inflammation |
Includes |
Anterior |
Anterior chamber |
Iritis |
uveitis |
|
Iridocyclitis |
|
|
Anterior cyclitis |
Intermediate |
Vitreous |
Pars planitis |
uveitis |
|
Posterior cyclitis |
|
|
Hyalitis |
Posterior |
Retina or choroid |
Focal, multifocal, or diffuse |
uveitis |
|
choroiditis |
|
|
Chorioretinitis |
|
|
Retinochoroiditis |
|
|
Retinitis |
|
|
Neuroretinitis |
Panuveitis |
Anterior chamber, vitreous |
All intraocular structures |
|
and retina, or choroid |
|
|
|
|
Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT (2005). Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol 140:509–516.
Clinical classification
The most recent clinical classification of uveitis is outlined in Table 11.2. Clinical behavior may be further described in terms of onset, duration, and course of uveitis (Table 11.3).
Pathological classification
Pathological classification separates granulomatous and nongranulomatous uveitis. The term granulomatous is sometimes used in the clinical context to describe uveitis with large, greasy, mutton-fat keratic precipitates (macrophages) and iris nodules (which may include Koeppe and Busacca nodules).
CLASSIFICATION OF UVEITIS (1) 317
Table 11.2 Proposed clinical classification of uveitis (IUSG, 2005)
Group |
Subgroup |
Infectious |
Bacterial |
|
Viral |
|
Fungal |
|
Parasitic |
|
Others |
Noninfectious |
Known systemic association |
|
No known systemic association |
Masquerade |
Neoplastic |
|
Non-neoplastic |
|
|
Table 11.3 Descriptors of uveitis (SUN 2005)
Type |
Descriptor |
Definition |
Onset |
Sudden |
|
|
Insidious |
|
Duration |
Limited |
3 months |
|
Persistent |
>3 months |
Course |
Acute |
Sudden onset + limited duration |
|
Recurrent |
Repeated episodes; inactive periods 3 months |
|
|
off treatment |
|
Chronic |
Persistent; relapse in <3 months off treatment |
|
|
|
Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT (2005). Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol 140:509–516.
However, this is strictly a histological term and is not accurate as a clinical descriptor. Indeed, this clinical picture may be seen in diseases with nongranulomatous histopathology, and true granulomatous diseases may present with nongranulomatous uveitis.
Etiological classification
An etiological classification helps define the cause, context, and treatment options for the disease, but in many patients a true etiology is never found.
318 CHAPTER 11 Uveitis
Classification of uveitis (2)
Differential diagnosis of uveitis by anatomical type
Table 11.4 Differential diagnosis of uveitis by anatomical location
Anterior |
|
|
JIA |
|
|
|
FHI |
|
|
|
Sarcoidosis |
|
|
|
Syphilis |
|
|
|
Posner–Schlossman |
|
|
|
Behcet’s disease |
|
|
|
HSV, VZV |
Intermediate |
|
|
Idiopathic (pars planitis) |
|
|
|
MS |
|
|
|
Sarcoidosis |
|
|
|
IBD |
|
|
|
Lyme disease |
Posterior |
Retinitis |
Focal |
Onchocerciasis |
|
|
|
Cysticercosis |
|
|
|
Masquerade |
|
|
Multifocal |
HSV |
|
|
|
VZV |
|
|
|
CMV |
|
|
|
Sarcoidosis |
|
|
|
Masquerade |
|
|
|
Candidiasis |
|
Choroiditis |
Focal |
Idiopathic |
|
|
|
Toxocariasis |
|
|
|
TB |
|
|
|
Masquerade |
|
|
Multifocal |
Sympathetic ophthalmia |
|
|
|
VKH |
|
|
|
Sarcoidosis |
|
|
|
Serpiginous |
|
|
|
Birdshot |
|
|
|
Masquerade |
|
|
|
MEWDS |
Panuveitis |
|
|
Idiopathic |
|
|
|
Sarcoidosis |
|
|
|
Behçet’s disease |
|
|
|
VKH |
|
|
|
Infective endophthalmitis |
|
|
|
Syphilis |
|
|
|
|
CMV, cytomegalovirus; FHI, Fuchs heterochromic iridocyclitis; HSV, herpes simplex virus; IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis; MEWDS, multiple evanescent white dot syndrome; MS, multiple sclerosis; POHS, presumed ocular histoplasmosis syndrome; TB, tuberculosis; VKH, Vogt–Koyanagi–Harada syndrome; VZV, varicella zoster virus.
UVEITIS: ASSESSMENT 319
Uveitis: assessment
All patients require a detailed history (ophthalmic and general) and a thorough ophthalmic examination, including dilated funduscopy of both eyes. In some cases a systemic examination may also be necessary (see Table 11.5).
For example, an apparently classic acute anterior uveitis may have posterior segment involvement (notably CME), may be secondary to more posterior disease (e.g., toxoplasmosis retinochoroiditis), or may be part of a panuveitis (e.g., sarcoid) and have systemic involvement.
Table 11.5 An approach to assessing uveitis
Symptoms |
Anterior: photophobia, redness, watering, pain, dVA; may be |
|
|
asymptomatic |
|
|
Intermediate: floaters, photopsia, dVA |
|
|
Posterior: dVA, photopsia, floaters, scotoma |
|
POH |
Previous episodes and investigations; surgery/trauma |
|
PMH |
Arthropathies (e.g., ankylosing spondylitis), chronic infections |
|
|
(e.g., HSV, TB), systemic inflammation (e.g., sarcoid, Behcet’s |
|
|
disease) |
|
Region of systems |
Detailed review of all systems |
|
FH |
Family members with uveitis or related diseases |
|
SH |
Travel or residence abroad, pets, IV drugs, sexual history |
|
Drug history |
Including any systemic immunosuppression |
|
Allergies |
Allergies or relevant drug contraindications |
|
Visual acuity |
Best-corrected/pinhole; near |
|
|
||
Visual function |
Check for RAPD, color vision |
|
Conjunctiva |
Circumcorneal injection |
|
Cornea |
Band keratopathy, keratic precipitates (distribution, size, |
|
|
pigment) |
|
AC |
Flare/cells, fibrin, hypopyon |
|
Gonioscopy |
PAS (consider if iIOP) |
|
Iris |
Transillumination defects/sectoral atrophy, miosis, posterior |
|
|
synechiae, heterochromia, Koeppe or Busacca nodules |
|
Lens |
Cataract, aphakia/pseudophakia |
|
Tonometry |
IOP |
|
Dilated |
Noncontact handheld lens ± indirect/indenting |
|
funduscopy |
|
|
Vitreous |
Haze, cells, snowballs, opacities, subhyaloid precipitates |
|
|
(KP-like but on posterior vitreous face) |
|
320 |
CHAPTER 11 Uveitis |
||
|
|
|
|
|
Table 11.5 (Contd.) |
|
|
|
Optic disc |
Disc swelling, glaucomatous changes, atrophy |
|
|
Vessels |
Inflammation (sheathing, leakage), ischemia (B/CRAO, B/ |
|
|
|
CRVO, retinal edema), occlusion |
|
|
Retina |
CME, unior multifocal retinitis (blurred white lesions may |
|
|
|
progress to necrosis, atrophy, or pigmentation) |
|
|
Choroid |
Unior multifocal choroiditis (deeper yellow-white lesions), |
|
|
|
associated exudative retinal detachment |
|
|
|
|
|
Grading of activity
Grading of AC flare and cells is not difficult and a useful indicator of disease activity (Tables 11.6 and 11.7). Activity within the vitreous is harder to assess: quantification of vitreous cells is of limited use due to their persistence; degree of vitreous haze is a more useful indicator.
Table 11.6 Grading of AC flare
Grade |
Description |
0 |
None |
1+ |
Faint |
2+ |
Moderate (iris + lens clear) |
3+ |
Marked (iris + lens hazy) |
4+ |
Intense (fibrin or plastic aqueous) |
|
|
Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT (2005). Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol 140:509–516.
Table 11.7 Grading of AC cells (counted with 1 x 1 mm slit)
Activity |
Cells |
0 |
<1 |
0.5+ |
1–5 |
1+ |
6–15 |
2+ |
16–25 |
3+ |
26–50 |
4+ |
>50 |
|
|
Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT (2005). Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol 140:509–516.
SYMPTOMS OF SYSTEMIC DISEASE IN UVEITIS 321
Symptoms of systemic disease in uveitis
Table 11.8 Systemic review that may provide clues to underlying disease
System |
Symptom |
Associated disease |
|
|
CVS |
Chest pain—pericarditis |
TB, RA, SLE |
|
|
|
Chest pain—myocarditis |
Syphilis |
|
|
|
Palpitations |
Sarcoidosis, ankylosing spondylitis, |
|
|
|
|
syphilis, RA, SLE, HIV |
|
|
|
Edema—cardiac failure |
TB, sarcoidosis, syphilis, RA, SLE, HIV |
|
|
|
Edema—IVC obstruction |
Behçet’s disease |
|
|
RS |
Cough |
TB, sarcoidosis, Wegener’s |
|
|
|
|
granulomatosis, HIV, toxocariasis |
|
|
|
Hemoptysis |
TB, Wegener’s granulomatosis, HIV, |
|
|
|
|
RA, SLE, sarcoidosis |
|
|
|
Stridor |
Relapsing polychondritis |
|
|
|
Chest pain—pleuritic |
Sarcoidosis, TB, Wegener’s |
|
|
|
|
granulomatosis, SLE, RA, lymphoma, |
|
|
|
|
HIV |
|
|
|
Shortness of breath |
Sarcoidosis, TB, Wegener’s |
|
|
|
|
granulomatosis, SLE, RA, HIV |
|
|
GI |
Diarrhea |
IBD, Behçet’s, HIV |
|
|
|
Blood and/or mucus in stools |
IBD, Behçet’s, HIV |
|
|
|
Jaundice |
IBD (with cholangitis or hepatitis) |
|
|
|
|
|||
|
|
toxoplasmosis, HIV |
|
|
GU |
Dysuria/discharge |
Reiter’s, syphilis, TB |
|
|
|
Hematuria |
Wegener’s granulomatosis, IgA |
|
|
|
|
nephropathy, TINU, SLE, TB |
|
|
|
Genital ulcers |
Behçet’s, syphilis, HLA-B27-related |
|
|
|
|
disease |
|
|
|
Testicular pain |
Behçet’s, HLA-B27-related disease, |
|
|
|
|
polyarteritis nodosum |
|
|
ENT |
Deafness or tinnitus |
VKH, sympathetic ophthalmia, |
|
|
|
|
Wegener’s granulomatosis, Cogan’s |
|
|
|
|
syndrome |
|
|
|
Earlobe pain and/or swelling |
Relapsing polychondritis |
|
|
|
Oral ulcers |
Behçet’s, HSV, HLA-B27-related |
|
|
|
|
disease, SLE |
|
|
|
Sinus problems |
Wegener’s granulomatosis |
|
|
|
Recurrent epistaxis |
Wegener’s granulomatosis |
|
|
322 |
CHAPTER 11 Uveitis |
|
|
|
|
Table 11.8 (Contd.) |
|
|
|
|
|
|
|
|
|
System |
Symptom |
Associated disease |
|
|
|
|
|
|
|
MusculoJoint pain, swelling, or |
HLA-B27-related arthropathies, |
||
|
skeletal |
stiffness |
JIA, sarcoidosis, RA, SLE, |
|
|
|
|
Behçet’s, relapsing polychondritis, |
|
|
|
|
Wegener’s, Lyme |
|
|
|
Lower back pain |
HLA-B27-related arthropathies, TB |
|
|
Skin |
Rash—erythema nodosum |
Sarcoidosis, Behçet’s, TB, IBD |
|
|
|
Rash—vesicular |
HSV, VZV |
|
|
|
Rash—other |
Psoriasis, syphilis, Lyme, SLE, |
|
|
|
|
Behçet’s, Reiter’s, JIA, TB |
|
|
|
Photosensitivity |
SLE |
|
|
|
Vitiligo |
SLE, VKH, sympathetic ophthalmia, |
|
|
|
|
leprosy |
|
|
|
Alopecia |
SLE, VKH |
|
|
|
Raynaud’s phenomenon |
SLE, RA |
|
|
CNS |
Headaches |
Sarcoidosis, VKH, Behçet’s, TB, SLE, |
|
|
|
|
lymphoma |
|
|
|
Seizures |
Sarcoidosis, VKH, Behçet’s, SLE, |
|
|
|
|
HIV, toxoplasmosis, lymphoma |
|
|
|
Weakness |
MS, sarcoidosis, Behçet’s, HIV, |
|
|
|
|
leprosy, syphilis, toxoplasmosis, |
|
|
|
|
lymphoma |
|
|
|
Numbness and/or tingling |
MS, sarcoidosis, Behçet’s, HIV, |
|
|
|
|
leprosy, lymphoma |
|
|
|
Loss of balance |
MS, sarcoidosis, Behçet’s, VKH, HIV, |
|
|
|
|
syphilis, lymphoma |
|
|
|
Speech problems |
MS, sarcoidosis, Behçet’s, HIV, |
|
|
|
|
lymphoma |
|
|
|
Behavior change |
VKH, sarcoidosis, Behçet’s, SLE, |
|
|
|
|
Wegener’s granulomatosis, HIV, TB, |
|
|
|
|
syphilis, lymphoma |
|
|
General |
Fever/night sweats |
JIA, lymphoma, VKH, SLE, RA, IBD, |
|
|
|
|
sarcoidosis, Kawasaki disease |
|
|
|
Swollen glands |
Sarcoidosis, lymphoma, HIV, JIA, TB, |
|
|
|
|
RA, syphilis, toxoplasmosis |
|
|
|
|
|
|
HIV, human immunodeficiency virus; HSV, herpes simplex virus; IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TB, tuberculosis; TINU, tubulointerstitial nephritis with uveitis; VKH, Vogt–Koyanagi–Harada syndrome; VZV, varicella zoster virus.
INVESTIGATIONS IN UVEITIS 323
Investigations in uveitis
When to investigate
Ideally, one would perform the minimum number of investigations to obtain the maximum amount of information. The usefulness of each test will depend on the pretest probability of the diagnosis and the specificity and sensitivity of the test. Consider also the potential morbidity of certain tests (e.g., FA or vitreous biopsy). In general, investigations may be performed for the following:
•Diagnosis: by identifying causative or associated systemic disease; by identifying a definite etiology (e.g., an organism).
•Management: monitoring disease activity or complications (e.g., OCT for macular edema); monitoring potential side effects of treatment (e.g., blood tests for some immunosuppressants).
Role in diagnosis
The etiology of most cases of uveitis is not known, although an autoimmune or autoinflammatory cause is often theorized. In most cases, a careful history and examination provides most if not all of the information need for diagnosis (see Table 11.9).
Some uveitis syndromes like FHI, Behçet’s, and toxoplasmosis are diagnosed purely on clinical grounds. Investigations are helpful in identifying uveitis of infective origin (e.g., TB, HSV) or systemic disease (e.g., lymphoma, sarcoidosis, demyelination). The role of some investigations is controversial (e.g., when to test HLA-B27 status).
Role in management
Monitoring disease
This is done almost entirely by clinical examination; however, in certain situations investigations may be helpful. For example:
•Optical coherence tomography (OCT) is extremely useful in establishing macular causes of worsening vision, particularly where clinical diagnosis is difficult because of poor visualization or preexisting macular disease (e.g., epiretinal membrane, CME, macular hole); this has largely replaced FA for this purpose.
•Fluorescein angiography (FA) is particularly helpful in assessing retinal vascular involvement and neovascularization.
•Electroretinogram (ERG) is required for monitoring birdshot retinochoroidopathy.
•Visual fields: for monitoring optic nerve damage due to either disease or associated iIOP or AZOOR complex disorders.
Monitoring therapies
Regular BP, weight, BM, and urinalysis are recommended for patients on systemic corticosteroids. Blood tests (e.g., CBC, urinalysis, LFT) are necessary for some of the other immunosuppresive agents (p. 709).
324 CHAPTER 11 Uveitis
Table 11.9 Suggested investigations in diagnosis of uveitis types
|
Investigation |
Consider |
Baseline |
CBC |
|
|
ESR |
|
|
Syphilis serology |
Syphilis |
|
ANA (in children) |
|
|
Urinalysis |
TINU (protein), diabetes |
|
Chest X-ray |
(glucose) |
|
|
TB, sarcoidosis |
Selective ACE ANCA
Toxoplasma serology Toxocara ELISA Borrelia serology HLA-B27
HLA-A29
Mantoux test
FA
Electrophysiology
Ultrasound B-scan
High-resolution CT thorax
CT orbits
MRI head scan
Gallium scan
Lumbar puncture
Conjunctival biopsy
PCR of intraocular fluid
Vitreous biopsy
Choroidal biopsy
Sarcoidosis Wegener’s (PR3) Toxoplasmosis Toxocariasis Lyme disease
B27-associated disease
Birdshot retinochoroidopathy
TB, sarcoidosis
Sarcoidosis
Demyelination, sarcoidosis, lymphoma
Sarcoidosis Demyelination, lymphoma Sarcoidosis
Infection
Infection, lymphoma
Lymphoma
ACUTE ANTERIOR UVEITIS (AAU) 325
Acute anterior uveitis (AAU)
Anterior uveitis accounts for ~75–90% of all cases of uveitis. Representing a wide spectrum of disease, it may be isolated, part of a panuveitis, or part of a systemic disease.
Idiopathic acute anterior uveitis
Approximately 50% of patients with AAU have the disease in isolation (i.e., HLA-B27 negative with no underlying systemic disease). The condition affects any age (biphasic peaking at 30 and 60 years) and both sexes equally. It is almost always unilateral but may affect both eyes sequentially. Recurrences are common.
Clinical features
•Pain, photophobia, redness, blurred vision.
•Limbal injection, keratic precipitates (especially inferior), AC flare/cells, posterior synechiae (PS), vitreous cells.
Treatment
Treat with frequent potent topical steroid (e.g., dexamethasone 0.1% or prednisolone acetate 1% up to every 30 min initially, titrating according to disease) and dilate (e.g., cyclopentolate 1% 3x/day; atropine 1% 3x/day in severe cases)—this may be the only chance to break the synechiae. If there is poor dilation, consider subconjunctival injection of lidocaine/phenylephrine; subconjunctival dexamethasone may also be necessary.
If there is no response after 48 hours of half-hourly drops, the patient may require expert consultation (e.g., consideration of oral steroids). In recalcitrant cases, subtenons triamcinolone injections or immunosuppression may be needed to control the uveitis. More recently, biological agents such as infliximab have also been beneficial for treatment.
HLA-B27-associated AAU
Up to 50% of patients with AAU are HLA-B27 positive (cf. 8% in the general population) (see Table 11.10). HLA-B27-related disease peaks at 30 years of age, is more common in males, and is associated with a positive family history. The diagnosis may be associated with ankylosing spondylitis, Reiter’s disease, and, less commonly, psoriasis or inflammatory bowel disease (IBD).
It is almost always unilateral but may affect both eyes sequentially (alternating); rarely, it may become persistent. Inflammation is often more severe and recurrences are more frequent than in idiopathic AAU.
Clinical features
•Pain, photophobia, redness, blurred vision.
•Anterior segment inflammation may be severe: circumlimbal injection, keratic precipitates (especially inferior), AC flare/cells/fibrin ± hypopyon, posterior synechiae, vitreous spillover cells.
Treatment
The treatment is the same as for idiopathic AAU.
